MYOV logo

Myovant Sciences (MYOV) Stock

Profile

Full Name:

Myovant Sciences Ltd.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United Kingdom

IPO:

27 October 2016

Indexes:

Not included

Website:

http://myovant.com

Description:

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.

Key Details

Price

-

Market Cap

-

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$230.97 M(+289.39% YoY)

Annual EPS

-$2.22(+21.55% YoY)

PE Ratio

-

Annual ROE

43.50%

Annual Debt To Equity

-0.76

Beta

-

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

May 10, 2023

Recent annual earnings:

May 10, 2023
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

26 Oct '22 Evercore ISI Group
In-Line
25 Oct '22 SVB Leerink
Market Perform
24 Oct '22 Baird
Neutral
09 Aug '22 SVB Leerink
Outperform
28 July '22 Goldman Sachs
Neutral
11 May '22 Goldman Sachs
Neutral
13 Apr '22 SVB Leerink
Market Perform
16 Feb '22 SVB Leerink
Market Perform
05 Jan '22 SVB Leerink
Market Perform
27 Oct '21 SVB Leerink
Market Perform

Screeners with MYOV included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price All-time High

$27.62
MYOV price is currently at an all-time high

Price Analysts Target

$27.00
MYOV price is currently equal to the consensus analysts' forecast

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Revenue Estimate

$419.54 M
MYOV annual revenue is currently -44.95% lower than the consensus analysts' forecast

Annual Net Income 3-Year Change

+24.7%
MYOV annual net profit is up +24.7% over the past 3 years

Annual EPS 3-Year Change

+45.72%
MYOV annual earnings per share is up +45.72% over the past 3 years

Annual EPS Estimate

-$1.69
MYOV annual earnings per share is currently +31.36% higher than the consensus analysts' forecast

Annual Gross Profit

$179.42 M
MYOV annual gross profit is $179.42 million

Annual Operating Profit

-$187.35 M
MYOV annual operaing income is -$187.35 million

Annual Operating Profit 3-Year Change

+29.26%
MYOV annual operaing income is up +29.26% over the past 3 years

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual ROE

43.50%
MYOV annual return on equity is 43.50%

Annual ROA

-33.09%
MYOV annual return on assets is -33.09%

Annual EBIT

-$186.96 M
MYOV annual earnings before interest & taxes is -$186.96 million

Annual EBITDA

-$183.89 M
MYOV annual earnings before interest, taxes, depreciation & amortization is -$183.89 million

Annual Interest Coverage Ratio

-13.38
MYOV annual interest coverage ratio is -13.38

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Quick Ratio

1.92
MYOV annual quick ratio is 1.92

Annual Current Ratio

1.95
MYOV annual current ratio is 1.95

Annual Total Assets

$520.01 M
MYOV annual total assets is $520.01 million

Annual Current Assets

$488.14 M
MYOV annual total current assets is $488.14 million

Annual Total Liabilities

$993.49 M
MYOV annual total liabilities is $993.49 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual CFO 3-Year Change

-19.85%
MYOV annual cash flow from operations is down -19.85% over the past 3 years

Annual CFI 3-Year Change

-1358.09%
MYOV annual cash flow from investing activities is down -1358.09% over the past 3 years

Annual CFF 3-Year Change

-90.54%
MYOV annual cash flow from financing activities is down -90.54% over the past 3 years

Annual CAPEX

$974.00 K
MYOV annual capital expenditures is $974.00 thousand

Annual FCF

-$269.53 M
MYOV annual free cash flow is -$269.53 million

Annual FCF 3-Year Change

-19.62%
MYOV annual free cash flow is down -19.62% over the past 3 years

Institutional Ownership

Similar stocks

FAQ

  • What is the primary business of Myovant Sciences?
  • What is the ticker symbol for Myovant Sciences?
  • Does Myovant Sciences pay dividends?
  • What sector is Myovant Sciences in?
  • What industry is Myovant Sciences in?
  • What country is Myovant Sciences based in?
  • When did Myovant Sciences go public?
  • Is Myovant Sciences in the S&P 500?
  • Is Myovant Sciences in the NASDAQ 100?
  • Is Myovant Sciences in the Dow Jones?
  • When was Myovant Sciences's last earnings report?
  • When does Myovant Sciences report earnings?
  • Should I buy Myovant Sciences stock now?

What is the primary business of Myovant Sciences?

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.

What is the ticker symbol for Myovant Sciences?

The ticker symbol for Myovant Sciences is NYSE:MYOV

Does Myovant Sciences pay dividends?

No, Myovant Sciences does not pay dividends

What sector is Myovant Sciences in?

Myovant Sciences is in the Healthcare sector

What industry is Myovant Sciences in?

Myovant Sciences is in the Biotechnology industry

What country is Myovant Sciences based in?

Myovant Sciences is headquartered in United Kingdom

When did Myovant Sciences go public?

Myovant Sciences's initial public offering (IPO) was on 27 October 2016

Is Myovant Sciences in the S&P 500?

No, Myovant Sciences is not included in the S&P 500 index

Is Myovant Sciences in the NASDAQ 100?

No, Myovant Sciences is not included in the NASDAQ 100 index

Is Myovant Sciences in the Dow Jones?

No, Myovant Sciences is not included in the Dow Jones index

When was Myovant Sciences's last earnings report?

Myovant Sciences's most recent earnings report was on 10 May 2023

When does Myovant Sciences report earnings?

The date for Myovant Sciences's next earnings report has not been announced yet

Should I buy Myovant Sciences stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions